We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Proof of Concept Study of PEMF (Pulsed Electromagnetic Field) Therapy in Subjects With Osteoarthritis of the Knee

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02696083
Recruitment Status : Completed
First Posted : March 2, 2016
Results First Posted : January 12, 2018
Last Update Posted : January 12, 2018
Information provided by (Responsible Party):
Regenesis Biomedical, Inc.

Brief Summary:
To investigate the effect of PEMF treatment when administered twice daily over a 90-day period by looking at synovial fluid in subjects with osteoarthritis of the knee.

Condition or disease Intervention/treatment Phase
Osteoarthritis, Knee Device: Provant Therapy System Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 19 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multicenter, Open-Label, Single-Arm, Proof of Concept Study of Pulsed Electromagnetic Field (PEMF) Therapy to Evaluate Synovial Fluid Markers in Subjects With Osteoarthritis of the Knee
Actual Study Start Date : February 2, 2016
Actual Primary Completion Date : September 23, 2016
Actual Study Completion Date : September 23, 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Osteoarthritis

Arm Intervention/treatment
Experimental: Active Treatment Device: Provant Therapy System

Primary Outcome Measures :
  1. Number of Synovial Markers Showing a Reduction From Baseline Following Treatment at Days 45 and 90 [ Time Frame: Baseline, Days 45 and 90 ]
    Synovial markers measured included bone morphologic proteins, related proteins Activin A, Osteoactivin, sonic hedgehog, Dickkopf, interleukin cytokines and tumor necrosis factor alpha, Growth Factors and Related Proteins fibroblast growth factors 1,2, androgen receptor, platelet derived growth factor BB, tumor growth factor beta, osteprogenerin, osteopontin, and Insulin like growth factor-1. Inflammation related proteins assayed were monocyte chemoattractant protein-1, macrophage colony-stimulating factor, macrophage inflammatory protein, receptor activator of Nuclear factor κ, and TNF related activation induced cytokine. Adhesion and matrix metalloproteinase proteins levels were also determined. The mean protein concentration was calculated for these markers at Baseline (n=19), Day 45 (n=7) and Day 90 (n=6).

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   45 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. Subject age is greater than or equal to 45 years and less than 80 years of age.
  2. Subject has documented Kellgren-Lawrence radiograph score of 2, 3, or 4. Attempts will be made to include at least 3 subjects in each category.
  3. Subject is on a stable analgesic regimen for at least two weeks prior to the Screening Visit and anticipates being able to remain on that regimen throughout the study.
  4. Subject is willing and able to give written informed consent and to comply with all parts of the study protocol.
  5. Female subjects must be post-menopausal, surgically sterile, abstinent, or practicing (or agree to practice) an effective method of birth control if they are sexually active for the duration of the study. (Effective methods of birth control include prescription hormonal contraceptives, intrauterine devices, double-barrier methods, and/or male partner sterilization).

Exclusion Criteria:

  1. Subject has documented Kellgren-Lawrence radiograph score of 1.
  2. Subject has undergone viscosupplementation treatment for the knee within 2 months of the Screening Visit.
  3. Subject has had a total or partial knee replacement.
  4. Subject has used topical or oral steroids within 2 months of the Screening Visit.
  5. Subject has undergone any anesthetic injection into the knee within 30 days prior to the Screening Visit or within 6 weeks prior to the Screening Visit for long acting lidocaine injection products.
  6. Subject has other diseases of the knee joint including inflammatory arthritis (i.e., rheumatoid arthritis, spondyloarthritis, gout and pseudogout), autoimmune disease (i.e., connective tissue disorders), septic arthritis, previous knee injury or intra-articular fracture.
  7. Subject will be unable to treat daily over the course of the 90 day treatment period (e.g., travelling without the ability to take Provant).
  8. Subject has received any investigational drug or device within 30 days or 5 half-lives of the drug, whichever is longer, prior to the Screening Visit or is enrolled in another clinical trial.
  9. Subject has a history of a solid tumor that is not in complete remission for greater than 2 years other than successfully treated non-metastatic basal cell or squamous cell carcinomas of the skin in the treatment area.
  10. Subject has a history of blood cancer (e.g., leukemia, lymphoma, multiple myeloma).
  11. Subject has an ongoing painful condition, other than osteoarthritis, that in the opinion of the investigator might have a confounding influence on the safety or effectiveness analyses for this study.
  12. Subject has a Body Mass Index (BMI) > 38 kg/m2.
  13. Subject has a serious psychosocial co-morbidity.
  14. Subject has a history of drug or alcohol abuse within one year prior to screening.
  15. Subject has an implanted pacemaker, defibrillator, neurostimulator, spinal cord stimulator, bone stimulator, cochlear implant, or other implanted device with an implanted metal lead(s).
  16. Subject is currently pregnant or planning on becoming pregnant prior to Day 90.
  17. Subject is unwilling or unable to follow study instructions, or comply with the treatment regimen, study visits, and diary entries.
  18. Subject is in current litigation regarding knee pain or is receiving Worker's Compensation.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02696083

Layout table for location information
United States, Colorado
Colorado Orthopaedics
Lone Tree, Colorado, United States, 80124
United States, Washington
Spokane Joint Replacement
Spokane, Washington, United States, 99218
Sponsors and Collaborators
Regenesis Biomedical, Inc.
Layout table for additonal information
Responsible Party: Regenesis Biomedical, Inc.
ClinicalTrials.gov Identifier: NCT02696083    
Other Study ID Numbers: RBI.2015.004
First Posted: March 2, 2016    Key Record Dates
Results First Posted: January 12, 2018
Last Update Posted: January 12, 2018
Last Verified: December 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Osteoarthritis, Knee
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases